Median progression-free survival was 100 months ( 95 % CI 88-108 ) in the cetuximab group and 103 months ( 98-113 ) in the bevacizumab group ( hazard ratio [ HR ] 106 , 95 % CI 088-126 ; p = 055 ) ; however , median overall survival was 287 months ( 95 % CI 240-366 ) in the cetuximab group compared with 250 months ( 227-276 ) in the bevacizumab group ( HR 077 , 95 % CI 062-096 ; p = 0017 ) .